We are studying a shorter chemotherapy treatment combined with Pembrolizumab for patients with PD-L1-positive recurrent or metastatic head and neck cancer. The goal is to see if this approach is effective and safe compared to standard treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a type of cancer that arises in the squamous cells lining the head and neck region. It can be recurrent or metastatic, meaning it can return after treatment or spread to other parts of the body.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.